Kamada (NASDAQ: KMDA; TASE: KMDA.TA) will release its financial results for the second quarter and first half ended June 30, 2026, before U.S. market open on Wednesday, August 12, 2026. Management will host a conference call that day at 8:30am Eastern Time to review the results.
Investors can join by phone via U.S., Israel, or international dial-in numbers using conference ID 13761830, or listen to a live webcast at the provided ViaVid link.
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the second quarter and first half ended June 30, 2026, prior to the open of the U.S. financial markets on Wednesday, August 12, 2026.
Kamada management will host an investment community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13761830. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1770235&tp_key=a29c72f53b.
About Kamada Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third-parties' pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.
When will Kamada (KMDA) report Q2 and first half 2026 financial results?
Kamada will report its Q2 and first half 2026 financial results on Wednesday, August 12, 2026, before the U.S. market opens. According to Kamada, the release covers the period ended June 30, 2026, followed by a same-day investor conference call.
What time is Kamada (KMDA) Q2 2026 earnings conference call on August 12, 2026?
Kamada’s Q2 and first half 2026 conference call is scheduled for 8:30am Eastern Time on August 12, 2026. According to Kamada, management will discuss results and answer questions from investors and analysts during the call.
How can investors join the Kamada (KMDA) Q2 2026 earnings call by phone?
Investors can join by dialing 1-877-407-0792 (U.S.), 1-809-406-247 (Israel), or 1-201-689-8263 (international) using conference ID 13761830. According to Kamada, these lines connect shareholders and interested parties to the live discussion.
Will Kamada (KMDA) provide a live webcast of its August 12, 2026 earnings call?
Yes. Kamada will webcast the August 12, 2026 earnings call live at https://viavid.webcasts.com/starthere.jsp?ei=1770235&tp_key=a29c72f53b. According to Kamada, the webcast offers online access for investors who prefer streaming over telephone participation.
What financial period will Kamada (KMDA) discuss on the August 12, 2026 call?
The call will cover financial results for the second quarter and first half ended June 30, 2026. According to Kamada, management will review performance for this period and respond to questions from the investment community.
